Hey 2 ...if you only get on this site once a week you have time to read this97%100-Day Survival Rate for Bone Marrow Transplants (2014-2016)86 Bone Marrow Transplants Performed (in 2016)Excellent bone marrow outcomes
Established in 1994, the Center for Cancer and Blood Disorders at Children’s Hospital Colorado offers the region’s only dedicated pediatric bone marrow transplant (BMT) program. We performed more than 80 bone marrow transplants in 2016 for children, teens and young adults with hematologic, oncologic, immunologic and hereditary metabolic conditions.
Children’s Colorado is recognized as meeting the highest standards of 100-day and one-year post-BMT survival compared to other U.S. pediatric BMT programs by the International Bone Marrow Transplant Registry, the NMDP and U.S. News and World Report. See our BMT survival rates.
Established in 1994, the Center for Cancer and Blood Disorders at Children’s Hospital Colorado offers the region’s only dedicated pediatric bone marrow transplant (BMT) program. We performed more than 80 bone marrow transplants in 2016 for children, teens and young adults with hematologic, oncologic, immunologic and hereditary metabolic conditions.
- We offer interventional clinical trials and research studies available only at limited institutions around the world. We also have a partnership with the North American Pediatric. We offer interventional clinical trials and research studies available only at limited institutions around the world.
Interesting that 23 specialist researchers from different centres in the US were involved in analysis of these trials. Did I not read somewhere that MSB could penetrate 50% of the market in the US by marketing to 30 facilities in the US? Looks like good progress to me…..but don’t let the facts get in the way of a falling share price . See below for list of participating hospitals with their specialist researchers.
https://www.childrenscolorado.org/doctors-and-departments/departments/cancer-and-blood-disorders/programs/bone-marrow-transplant/Just to put things in other perspective for certain posters . The above test results are facts shown on the hospitals own website . Cynata may have trouble enlisting patients for the clinical trials going forward when survival rates are 97% … but maybe I have got something wrong ?
How did they achieve such amazing results, which are saving so many young lives ? I decided to look again at MSB phase 3 results and Cynata phase 1 results and I noticed a rather interesting variation in the cohort groups. You can see from the link below for MSBs clinical trial that 89% of the 55 patients had grade C (iii) or D(IV) aGVHD which is the most severe with a 90% mortality rate . Obviously that infers that only 11%, or 6 patients were grade B (ii). This appears to contrast with Cynata who had only 9 out of 15 patients with the more severe designation 3 (C)... with no grade 4(IV) patients at all ! Interestingly only 5 out of the 9 patients in the C (iii) group had a complete response. These were patients A4,A7,A8,B2 and B3.
MSB results link for MSC-100-IV for steroid refractory aGVHD trials
d8c48d14-a0e1-4364-9c45-8e5aefa85428.png
Now look at (Page 17) of Cynata's latest presentation for their results
http://files.cynata.com/390/18.11.01.Cynata-Outlook-and-Investor-Presentation.pdf
Obviously I believe there is a major difference in mortality when treating patients in grade III & IV vs grade II
FYI ~I found a breakdown grading spectrum as follows:
This does not take away from Cynata’s excellent results . It is not their fault if they could not enlist a totally representative group for their cohort study ...but it does appear that MSB results were based on a cohort group of much sicker patients?……someone please correct me if I have this wrong ? If I am right ,we might be comparing very sick apples with extremely sick pears. I am not sure Fuji will be amused ….but then again I don’t think the Japanese will care to lose face having already spent a fortune trying to get into this area of medicine.
I must stress that I need to present my observations to Mesoblast and Cynata to get their feedback. It is dangerous, with no professional experience of evaluating clinical trial results ,for me to jump to conclusions, but on the basis of what I see ...I think comparisons are not fair or accurate . Please do not rely on my interpretation when making a decision to trades in the securities of either Company. DYOR.
Maybe certain posters on the CYN thread want to phone Amy Keating at the Colorado Hospital and find out…or one of the other 22 specialists around the UShttps://www.centerwatch.com/clinical-trials/listings/68909/grades-b-d-agvhd-prospective-study-remestemcel-l-/
A Prospective Study of Remestemcel-L Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Brief description of study
The study plans to treat at least 60 paediatric subjects, male and female, between the ages of 2 months and 17 years inclusive with acute Graft versus Host Disease (aGVHD) following allogeneic hematopoietic stem cell transplant (HSCT) that has failed to respond to treatment with systemic corticosteroid therapy. Subjects may have Grades C and D aGVHD involving the skin, liver and/or gastrointestinal (GI) tract or Grade B aGVHD involving the liver and/or GI tract, with or without concomitant skin disease.
Detailed Study Description
Remestemcel-L will be evaluated in pediatric subjects with acute Graft versus Host Disease (aGVHD) following allogeneic hematopoietic stem cell transplant (HSCT) that has failed to respond to treatment with systemic corticosteroid therapy.
Clinical Study Identifier: NCT02336230
Contact Investigators or Research Sites near you
Alicia McFarren, MD
Children's Hospital Los AngelesLos Angeles, CA United StatesSteven Neudorf, MD
Children's Hospital of Orange CountyOrange, CA United StatesYing Lu
University of California at San FranciscoSan Francisco, CA United StatesAmy Keating, MD
Children's Hospital Colorado Center for Cancer/Blood DisordersAurora, CO United StatesEmi Caywood, MD
Alfred I. DuPont Hospital for Children of the Nemours FoundationWilmington, DE United StatesMichael Joyce, MD
Nemours Children's Specialty CareJacksonville, FL United StatesSonali Chaudhury, MD
Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, IL United StatesLolie Yu, MD
Children's Hospital of New OrleansNew Orleans, LA United StatesJason Law, MD
Tufts Medical CenterBoston, MA United StatesGail Megason, MD
University of Mississippi Medical CenterJackson, MS United StatesGary Myers, MD
Children's Mercy HospitalKansas City, MO United StatesJoel Brochstein, MD
Cohen Children's Medical Center of NYNew Hyde Park, NY United StatesPrakash Satwani, MD
Columbia University Medical CenterNew York, NY United StatesSusan Prockop, MD
Memorial Sloan Kettering Cancer CenterNew York, NY United StatesKris Mahadeo, MD
Albert Einstein College of MedicineNew York, NY United StatesJoanne Kurtzberg, MD
Duke University Medical CenterDurham, NC United StatesEneida Nemecek, MD
Oregon UniversityPortland, OR United StatesMichelle Hudspeth, MD
Medical University of South CarolinaCharleston, SC United StatesVictor Aquino, MD
University of Texas Southwestern Medical CenterDallas, TX United StatesTroy Quigg, MD
Texas Transplant InstituteSan Antonio, TX United StatesChristina Wiedl, MD
Virginia Commonwealth University
Richmond, VA United States
Julie Talano, MD
Medical College of WisconsinMilwaukee, WI United StatesShalini Shenoy, MD
Washington UniversitySaint Louis, MO United StatesRecruitment Status: Closed
- Forums
- ASX - By Stock
- MSB
- MSB trading
MSB trading, page-3383
-
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
97.0¢ |
Change
-0.025(2.51%) |
Mkt cap ! $1.107B |
Open | High | Low | Value | Volume |
99.0¢ | $1.03 | 97.0¢ | $2.815M | 2.838M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 151781 | 97.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.5¢ | 80522 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 151781 | 0.970 |
5 | 72712 | 0.965 |
9 | 134156 | 0.960 |
4 | 43363 | 0.955 |
11 | 224934 | 0.950 |
Price($) | Vol. | No. |
---|---|---|
0.975 | 80522 | 1 |
0.990 | 33914 | 1 |
0.995 | 72449 | 5 |
1.000 | 61847 | 4 |
1.005 | 96389 | 3 |
Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |